Sage Therapeutics said Wednesday that its experimental anti-depression pill alleviated symptoms within three days of treatment, achieving the goal of a clinical trial involving patients with major depressive disorder.
The rapid antidepressant effect of the Sage drug, called zuranolone, is a novel feature that differentiates it from currently available drugs that are slower acting and might be taken for months, if not longer, Sage said.
The company intends to use the results from the study to help position zuranolone as an “episodic” treatment, meaning people with depression take the drug for two weeks and then stop.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
